Shares of Merck & Co. Inc. MRK slid 1.72% to $96.24 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.88% to 6,049.24 and ...

Merck (MRK) closed at $96.24 in the latest trading session, marking a -1.72% move from the prior day. This change lagged the S&P 500's daily gain of 0.88%. Elsewhere, the Dow saw an upswing of 1.24%, ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Disruptive analytics’ Substack by Magnus Ofstad. In this ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Shares of this pharmaceutical company have returned +1.2% over the past month versus the Zacks S&P 500 composite's -1.6% change. The Zacks Large Cap Pharmaceuticals industry, to which Merck ...

Merck and Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The time to step into quality dividend payers is when the crowd forgets there's never a bad time to own a high-quality stock.

Merck's human papillomavirus vaccine has been approved for men in China, it said on Wednesday, providing the U.S. drugmaker a ...